Literature DB >> 23689728

Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline.

George Sakoulas1, Poochit Nonejuie, Victor Nizet, Joseph Pogliano, Nancy Crum-Cianflone, Fadi Haddad.   

Abstract

A recurrent case of left-sided endocarditis caused by high-level aminoglycoside-resistant Enterococcus faecalis was successfully treated with ceftaroline and daptomycin. This combination demonstrated excellent synergy in vitro. Mechanistically, ceftaroline enhanced binding of daptomycin to the cell membrane and sensitized E. faecalis to killing by human cathelicidin LL-37, a cationic innate host defense peptide. Daptomycin plus ceftaroline may be considered in salvage therapy in E. faecalis endovascular infections and requires further study.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23689728      PMCID： PMC3719745          DOI： 10.1128/AAC.02481-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins.

Authors:  Joe Pogliano; Nicolas Pogliano; Jared A Silverman
Journal:  J Bacteriol       Date:  2012-06-01       Impact factor: 3.490

2.  Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Ann F Bolger; Matthew E Levison; Patricia Ferrieri; Michael A Gerber; Lloyd Y Tani; Michael H Gewitz; David C Tong; James M Steckelberg; Robert S Baltimore; Stanford T Shulman; Jane C Burns; Donald A Falace; Jane W Newburger; Thomas J Pallasch; Masato Takahashi; Kathryn A Taubert
Journal:  Circulation       Date:  2005-06-14       Impact factor: 29.690

Review 3.  Pharmacokinetics of sulbactam/ampicillin in humans: a review.

Authors:  G Foulds
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

4.  Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.

Authors:  George Sakoulas; Arnold S Bayer; Joseph Pogliano; Brian T Tsuji; Soo-Jin Yang; Nagendra N Mishra; Victor Nizet; Michael R Yeaman; Pamela A Moise
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

5.  Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone.

Authors:  Joan Gavaldà; Oscar Len; José M Miró; Patricia Muñoz; Miguel Montejo; Aristides Alarcón; Julián de la Torre-Cisneros; Carmen Peña; Xavier Martínez-Lacasa; Cristina Sarria; Germán Bou; José M Aguado; Enrique Navas; Joan Romeu; Francesc Marco; Carmen Torres; Pilar Tornos; Ana Planes; Vicenç Falcó; Benito Almirante; Albert Pahissa
Journal:  Ann Intern Med       Date:  2007-04-17       Impact factor: 25.391

6.  Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci.

Authors:  Kenneth H Rand; Herbert Houck
Journal:  J Antimicrob Chemother       Date:  2004-02-12       Impact factor: 5.790

7.  Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.

Authors:  Warren E Rose; Lucas T Schulz; David Andes; Rob Striker; Andrew D Berti; Paul R Hutson; Sanjay K Shukla
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

8.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

9.  Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

Authors:  Barry H Dvorchik; David Brazier; Michael F DeBruin; Robert D Arbeit
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
  9 in total
  26 in total

Review 1.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

Review 2.  Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.

Authors:  Sebastiano Leone; Silvana Noviello; Silvano Esposito
Journal:  Infection       Date:  2015-09-01       Impact factor: 3.553

3.  Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Authors:  Ashley D Hall Snyder; Brian J Werth; Poochit Nonejuie; John P McRoberts; Joe Pogliano; George Sakoulas; Juwon Yim; Nivedita Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  Is an aminoglycoside still required for the treatment of enterococcal endocarditis?

Authors:  Donald P Levine
Journal:  Curr Infect Dis Rep       Date:  2013-10       Impact factor: 3.725

5.  Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations.

Authors:  Brian J Werth; Laura M Shireman
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 6.  A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Authors:  Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

Review 7.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model.

Authors:  Seyedehameneh Jahanbakhsh; Nivedita B Singh; Juwon Yim; Razieh Kebriaei; Jordan R Smith; Katherine Lev; T T Tran; Warren E Rose; Cesar A Arias; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

9.  β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.

Authors:  Jordan R Smith; Katie E Barber; Animesh Raut; Mostafa Aboutaleb; George Sakoulas; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2015-02-01       Impact factor: 5.790

10.  Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium.

Authors:  George Sakoulas; Warren Rose; Poochit Nonejuie; Joshua Olson; Joseph Pogliano; Romney Humphries; Victor Nizet
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.